H.C. Wainwright raised the firm’s price target on Akero Therapeutics to $50 from $43 and keeps a Buy rating on the shares. The analyst believes the long-term data profile of efruxifermin offers potentially transformational benefits to fibrosis stage 2 or 3 patients. The firm has no concerns on safety or tolerability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKRO:
- Akero Therapeutics Announces Proposed Public Offering of Common Stock
- Akero Therapeutics’ EFX Shows Promise in Phase 2b MASH Study
- Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
- Akero Therapeutics reports results from Phase 2B HARMONY study
- Akero Therapeutics to host conference call